Key result
Adjunctive immunosuppression shows no benefit over corticosteroids alone for preventing cardiac sarcoidosis relapse.
Why the study?
Cardiac sarcoidosis is a life-threatening condition lacking clear recommendations, warranting an updated review of corticosteroid and immunosuppressive therapies.
Do corticosteroids and/or immunosuppressive therapies improve outcomes in patients with cardiac sarcoidosis?
Population
Patients with cardiac sarcoidosis across 21 studies
Comparison
Corticosteroids and/or immunosuppressive agents
Design
Systematic review
Authors
Loading...
Comparable relapse rates suggest limited benefit from adjunctive immunosuppression; leaves open whether combination therapy improves outcomes in cardiac sarcoidosis.
Systematic Review
Do corticosteroids and/or immunosuppressive therapies improve outcomes in patients with cardiac sarcoidosis?
Corticosteroids appear to have a positive impact on left ventricular function and arrhythmias in cardiac sarcoidosis, but high-quality evidence and data on adjunctive immunosuppressive therapies are lacking.
Stievenart et al. (2021) conducted a systematic review in Cardiac sarcoidosis. Corticosteroids and/or immunosuppressive agents was evaluated on Relapse rate, major cardiac adverse events (MACEs) and adverse events. In a systematic review of cardiac sarcoidosis, corticosteroids alone were associated with a 34% relapse incidence, while adjunctive immunosuppressive therapy had a 33% relapse incidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: